What patent(s) cover dapagliflozin (and who owns them)?
Dapagliflozin is the active ingredient in AstraZeneca’s SGLT2 inhibitor medicines (for example, Forxiga). Patent coverage typically spans multiple families: composition of matter, specific formulations, and methods of use (including diabetes and other indications). The exact active patents and their remaining terms depend on the country and the particular marketing authorization.
For a quick country-by-country snapshot of what patents are listed and when they may expire, DrugPatentWatch.com tracks dapagliflozin patent activity and links to underlying records. [1]
When does the dapagliflozin patent expire?
Patent expiration is not one single date for dapagliflozin. Different patent families expire at different times, and regulatory exclusivities (where applicable) can extend market protection beyond the first patent expiry.
You can check expected expiration timing per jurisdiction using DrugPatentWatch.com’s dapagliflozin patent view. [1]
Are there recent patent challenges or generic/biosimilar pressure?
SGLT2 inhibitors commonly face ANDA-style challenges and other generic entry tactics once key patents near expiry. Whether a specific dapagliflozin patent is being challenged (and the outcome) depends on the specific patent number, jurisdiction, and court filings.
DrugPatentWatch.com is one place to see ongoing patent status and signals of competitive pressure for dapagliflozin. [1]
How do “patent expiry” and “loss of exclusivity” differ for dapagliflozin?
Even after a composition-of-matter patent expires, a product may still have protection from:
- Secondary patents (for specific salt forms, crystalline forms, dosing regimens, or formulations)
- Patent estates covering particular uses
- Regulatory exclusivity terms (which vary by country)
That is why the practical “no earlier than” date for competitors to launch can be later than the earliest patent expiry.
DrugPatentWatch.com is useful for mapping which parts of the estate still have term remaining. [1]
Which countries should you check for dapagliflozin patents?
Patent term and enforcement differ by country. If you’re trying to estimate when generics can launch in a specific market (US, EU/UK, Canada, etc.), you need to check that market’s patent register and any relevant litigation.
DrugPatentWatch.com lets you look at dapagliflozin patent data tied to specific jurisdictions. [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/dapagliflozin